BNO 2.56% 8.0¢ bionomics limited

Oz Platinums BionomicsBNOtrade/invest/researchresi

  1. 4,330 Posts.
    ilrobbinrosso (ID#: 406483) RE: Cat & PwrChristoffa Oz Platinums BionomicsBNO 23/5/02 2:08:32 AM 5190824
    « Previous Message Next Message »

    Just as a speculative one Stoff should mention Oz Platinum's Bionomics, they are short term traders of stocks and you can see the "larrikinism" on the thread---with Rolo---going$$$$$pay day (lol) Oz Platinum though have this one as a longer term hold (not to say they wouldn't trade it or average out on occasions) (I don't know can't speak on their behalf) there are several small biotechs I like, but this one they have researched already (the hard yards have been done)--Ive had a bit of a snoop around the company announcement announcement section and it looks good, the sector is actually a tad bearish in the U.S.A. I checked with Barchart, looks improving though.
    Australian Bullish Consensus--see report entitled that onm the thread give a valuation (through time) of $1.45c---I wouldn't put a huge amount of money into it (many people do that as you know) but as one to put a few pennies in for a rainy day, they are only 8c per share--10.000 for 800 dollars---or even a thousand for 80 dollars sounds good, it got caught in the tech wreck as did many other companies.
    It has 11.3 million dollas in the bank ran at a small profit last time it reported of 100.000 dollars---has received Federal Government funding for research and development and has alliances with the majors, it has patents on the things it does and is involved in cancer research, if you haven't heard of the company already encourage you to have a look and see what you think.
    ---------------------------------------------------------------------

    ---------------------------------------------------------------------
    Cheers,--BK.
    ---------------------------------------------------------------------
    BIONOMICS LIMITED 2002-05-29 ASX-SIGNAL-G

    HOMEX - Adelaide

    +++++++++++++++++++++++++
    Bionomics Limited (ASX:BNO), today announced progress of its product
    development collaboration with the European and US-based company
    Genmab A/S to create and develop fully human antibodies to
    angiogenesis targets identified by Bionomics.

    Just two months into the collaboration, Bionomics' CEO and Managing
    Director, Deborah Rathjen said Bionomics and Genmab were progressing
    the development of antibody products by including a third Bionomics'
    target, one more than was initially proposed when the collaborative
    development deal was announced in March. Dr Rathjen also said that
    Bionomics and Genmab had formalized the steering and research
    committees that will manage the collaborative program.

    "We are now on track to seeing a first antibody product entering
    clinical phase within twoyears," said Dr Rathjen. "The three targets
    that are subject to the joint development program include a target in
    a chromosomal region that is amplified in several human cancers,
    particularly in lung and liver tumours."

    Industry estimates suggest that the treatment of lung cancer and
    liver cancer represent markets of at least US$2 billion each, on a
    global basis.

    All three targets are associated with the process of angiogenesis,
    which is involved in the growth of cancer and inflammatory diseases.

    "This is a very important partnership for Bionomics as the world
    antibody market is currently worth more than US$3 billion. Antibody
    products have shorter development times when compared with typical
    small molecule drug development. Working with Genmab will see
    Bionomics accelerate its product rollout from the lab to clinical use
    and human benefit," said Dr Rathjen.

    FOR FURTHER INFORMATION PLEASE CONTACT:

    Dr Deborah Rathjen
    CEO & MANAGING DIRECTOR
    Bionomics Limited
    Ph: +61 8 8354 6101

    Or visit the Bionomics website at www.bionomics.com.au
    ------------------------------------------------------------------------------------
    bullboard121 (ID#: 407073) Australian Bullish consensus Bionomics. 10/5/02 10:56:14 AM 5147927
    « Previous Message Next Message »

    The Australian Bullish Consensus Report - May 10, 2002
    The Australian Bullish Consensus Report - May 10, 2002 "This summary has been prepared independently of the brokers identified. This service does not have the sponsorship, affiliation or approval of those brokers. This report is meant as information about brokers recommendations of today. Subscribers should check the full text of the recommendations before making any investment decision and consult their financial advisor before acting on these recommendations to suit their particular circumstances."
    --------------------------------------------------------------------
    "The copyright in this summary is owned by OTS Financial News Pty Ltd ('OFN'). The summary may not be copied, forwarded or disseminated to any other person." http://www.consensusdaily.com
    --------------------------------------------------------------------
    SYDNEY (OFN) - Your Daily Summary of the major broker recommendation, valuation and forecast changes.
    --------------------------------------------------------------------
    Bullish Consensus Today (BCR): 41.67% AUSTRALIAN DOLLAR Morgan Stanley - Expect Australian dollar to rally to US$0.58 at year end. Forecast US$0.64 by end 2003. Wine producers seen as big losers. Estimate that a 10% rise in A$/US$ could erode 9% of operating profits of companies with large US Exposure.
    --------------------------------------------------------------------
    APRIL LABOUR FIGURES ABN Amro - Correction in April after several months of rises is not too much to worry about, with Easter and school holidays effecting the numbers. Leading employment indicators are still positive.
    --------------------------------------------------------------------
    CSFB - RBA would have expected the fall and is mostly just statistical noise. Employment growth still averaging 15,000/month.
    --------------------------------------------------------------------
    UBS Warburg - Decline largely expected and mainly, but not completely due to late Easter. Unemployment rate still at 6.3%.
    --------------------------------------------------------------------
    JB Were - Expect a large bounce back in employment numbers next month. Expect another RBA 25 bp Cash rate hike in June.
    --------------------------------------------------------------------
    INSURANCE SECTOR ABN Amro - NSW Motor Accident Authority data shows IAG and also QBE gaining market at the expense of Allianz. IAG's market share rose by 3.1% to 42.9% in the March quarter and QBE rose 0.6% to 11.2%.
    --------------------------------------------------------------------
    MAURITANIA DRILLING Macquarie - 100 mbbls is being claimed as being technically recoverable in first well. If this proves correct this would add 18cps to Woodside [WPL], 19cps to Hardman [HDR] and 8cps to Roc Oil [ROC].
    --------------------------------------------------------------------
    STEAMING COAL CSFB - 7.68% fall in steaming coal price is above forecast of 5% but less than some market expectation of 10%. Cut Rio Tinto [RIO] FY02 earnings by 1% and FY03 by 0.3%, BHP Billion [BHP] FY03 by 1% and MIM [MIM] FY02 by 2% and FY03 by 3%.
    --------------------------------------------------------------------
    ALINTAGAS LIMITED [ALN] $4.16 Macquarie - Downgrade to Marketperform/LT Outperform from Outperform/LT Outperform. Purely due to recent share price appreciation.
    --------------------------------------------------------------------
    AMCOR LIMITED [AMC] $7.68 Citigroup - Outperform, High Risk. Raised FY03 EPS by 22% to 64.2c, FY04 by 15% to 73.3c to take into account Schmalbach-Lubeca acquisition. Company has indicated that further significant acquisitions are out of the question for the time being given the size of this one.
    --------------------------------------------------------------------
    JP Morgan - Market Performer. PET acqusition sees FY03 EPS rise by 6% and is in line with company strategy, but at a full price.
    --------------------------------------------------------------------
    AMP LIMITED [AMP] $16.85 Goldman Sachs - Market Performer. Cut FY02 profit by 2% following 5% downgrading in Henderson earnings. Cut valuation by 55c to $19.15. Figures et for further review following May 16 AGM.
    --------------------------------------------------------------------
    AUSTAL LIMITED [ASB] $1.43 UBS Warburg - Upgrade to Buy. Following 15% fall in share price since last month and the announcement of a $24m ferry contract. 12 mth target $1.65.
    --------------------------------------------------------------------
    AXA ASIA PACIFIC HOLDINGS LIMITED [AXA] $3.03 Citigroup - Outperform, Medium Risk. Valuation $3.30. In-depth analysis shows company is now in a turn-around position, offsetting all previous unsuccessful attempts to reposition itself. Probability of significant improvements is now seen as high and might deliver valuation in excess of $4.
    --------------------------------------------------------------------
    AXON INSTRUMENTS INC [AXN] $0.37 Deutsche Bank - Marketperform. Cut target to $0.40 from $0.63. Finding a clear cut catalyst for this stock in the coming six months might prove difficult as all life science device companies are feeling effects of weak demand. Another loss-making six months, as flagged by management, will add more to current uncertainty. Cut FY03 EPS by 40% to $0.60. Believe company will have to show success in drug discoveries in H2 FY02 and FY03 to ensure sustainable long term growth.
    --------------------------------------------------------------------
    Hartleys - Hold (Under Review). Pending discussions with management following profit warning.
    --------------------------------------------------------------------
    BHP BILLITON LIMITED [BHP] $11.27 ABN Amro - Hold. Marketing teams decision to move away from 3rd party traders and to promote better customer relations is likely to lead to better understanding and may reduce cyclical nature of earnings.
    --------------------------------------------------------------------
    Merrill Lynch - Strong Buy/LT Strong Buy. Target $14.00. Cut FY02, FY03 forecasts in line with reported thermal coal settlement between Japan and Australia of 7% below last year's settlement. Still expect hard coking coal negotiations to come out positive for producers. Expect current downgrade to be more than offset.
    --------------------------------------------------------------------
    BIONOMICS LIMITED [BNO] $0.90 BNP Paribas - Outperform. Target $1.45. Believe that newly concluded deal with Johnson & Johnson adds weights to company's exceptional mid to long term potential. Despite continuously reaching its goals, market has yet to reward the company for it.
    --------------------------------------------------------------------
    Citigroup - Neutral, Speculative. Johnson & Johnson deal seen as raising credibility of company and its R&D portfolio but does not proof commercial viability of its 230 patented genes. Internationally, the trend shows that genomic discovery biotech stocks like Bionomics, are being required to validate their gene targets well into the preclinical stage before significant licensing deals are struck. This is one step in the process and analysts don't expect such a deal in the short term.
    COMMANDER COMMUNICATIONS LIMITED [CDR] $0.74 Citigroup - Outperform, High Risk. Company waits big challenges in the coming two years. Analysts think current valuation leaves ample room for upside on 12 mths view.

    CIRCADIAN TECHNOLOGIES LIMITED [CIR] $1.88 Hartleys - Under Review. Pending review of recommendation for Axon [AXN] in which the company holds a 15.4% stake.
    --------------------------------------------------------------------
    COLES MYER LTD. [CML] $6.35 Macquarie - Marketperform/LT Marketperform. Myer Grace Bros is terminally flawed. It will never generate the volumes and margins necessary to balance its high cost base. Kmart is fixable, but Grace Bros problems sees no market value attributed to non-food businesses. There are too many stores and many need to be closed.
    --------------------------------------------------------------------
    DEUTSCHE OFFICE TRUST [DOT] $1.27 Deutsche Bank - Downgrade to Marketperform from Buy. Target $1.31. Acquisition of 30-43 Hickson Road, Sydney seen as positive. Trust will have to show some progress on expiry of some lease contracts. Fair Value $1.38.
    --------------------------------------------------------------------
    FOODLAND ASSOCIATED LIMITED [FOA] $18.49 Citigroup - Outperform, Medium Risk. 3 sales largely reassuring group remains on track for FY02 profit. Stock remains moderately valued in retail sector.
    --------------------------------------------------------------------
    CSFB - Buy. Woolworths NZ acquisition could add $2.00-4.25 to current valuation of $18.22 and is likely to be a key factor in the stock's re-rating. 12 mth target $23.00. Lift earnings going forward by 1-1.5% due to higher projections.
    --------------------------------------------------------------------
    Deutsche Bank - Buy. Target $19.00. Q3 sales report slightly above expectations, with all businesses showing a positive trend. Re-rating to require more news on Woolworths New Zealand acquisition. Slightly raised forecasts.
    --------------------------------------------------------------------
    Hartleys - Take Profits. Q3 result marginally below forecast.
    --------------------------------------------------------------------
    JB Were - Buy. Lift valuation by 4% to $18.00. Lift FY02 profit by 2% to $92m, FY03 to $104m, FY04 to $118m. Following Q3 sales report.
    --------------------------------------------------------------------
    Merrill Lynch - Buy/LT Strong Buy. Q3 sales slightly above expectations.
    --------------------------------------------------------------------
    FAIRFAX (JOHN) HOLDINGS LIMITED [FXJ] $3.49 Citigroup - Neutral, Medium Risk. Valuation $3.32. Cut FY02 profit by 5.9% to $89m, FY03 by 15% to $116m. On lowered revenue expectations. View further declines in advertisement revenues as unlikely.
    --------------------------------------------------------------------
    GOODMAN FIELDER LIMITED [GMF] $1.61 Deutsche Bank - Buy. Target $1.85. Believe management should be able to drive solid EBIT margin growth over the medium term. Believe this has yet to be factored in. Valuation $1.81. Track record may hold some investors back.
    --------------------------------------------------------------------
    ILUKA RESOURCES LIMITED [ILU] $4.35 BNP Paribas - Upgrade to Outperform from Marketperform. Target $5.00. Believe share price has weakened to more realistic levels, representing better value in combination with a stable outlook. Cut FY02 EPS by 8.4% to 44.4c, FY03 by 12.7% to 53.7c, FY04 by 9.9% to 53.7c. Also, company has flagged a more aggressive growth strategy in combination with a better information flow to the financial markets. Company may well beat FY02 expectations.
    --------------------------------------------------------------------
    MACQUARIE GOODMAN INDUSTRIAL TRUST [MGI] $1.46 JB Were - Accumulate/LT Overweight. Lift earnings forecasts on pre-commitment Laminex to Greystanes Park project.
    --------------------------------------------------------------------
    Merrill Lynch - Neutral/LT Buy. Increased Net Present Value by 2c to $1.39. Lift distribution forecasts by 1c per unit for the years FY)3-FY04 on the basis of pre-development warehouse distribution center at Greystanes Park, Sydney. Sees sound investment portfolio with lots of growth opportunities.
    --------------------------------------------------------------------
    MIM HOLDINGS LIMITED [MIM] $1.26 Merrill Lynch - Strong Buy/LT Buy. Target $1.65. Cut FY02 profit to $83m from $89m, FY03 to $165m from $184m. On reported 7% lower thermal coal settlement between Japan-Australia. Net Present Value $1.55.
    --------------------------------------------------------------------
    NATIONAL AUSTRALIA BANK LIMITED [NAB] $34.80 BNP Paribas - Downgrade to Marketperform. Target $38.00. Realised H1 FY02 earnings are 4.5% below forecast. Cut FY02 profit in line with interim result. Prefer to wait for signs of revitalized revenue growth.
    --------------------------------------------------------------------
    Citigroup - Outperform, Low Risk. Valuation $37.87. H1 result mixed, including disappointing underlying profit growth. Slightly reduced forecasts.
    --------------------------------------------------------------------
    Deutsche Bank - Buy. Target $38.00. Remains preferred sector pick following H1 FY02 result. Minor changes to forecasts. Discounted Cash Flow valuation $37.61.
    --------------------------------------------------------------------
    Hartleys - Hold. H1 FY02 result slightly above expectation.
    --------------------------------------------------------------------
    JB Were - Hold/LT Buy. Valuation $34.20. Modestly cut forecasts following H1 FY02. Preferred sector investment due to broad market support.
    --------------------------------------------------------------------
    JP Morgan - Market Performer. Result 2.7% above forecast. Showing a declining business receivables base and strong housing growth. Earnings forecasts will be adjusted soon.
    --------------------------------------------------------------------
    Macquarie - Upgrade to Outperform/LT Outperform from Outperform/LT Marketperform. Very likely to achieve its EPS growth targets for FY03-04. Seen emerging as the bank with the fastest housing lending growth. Preferred banking stock.
    --------------------------------------------------------------------
    UBS Warburg - Hold. Result was weak but expected. It leaves H2 looking uncertain. Further buybacks and MSR sale may provide positive news flow but earnings concerns override cheap share price. 12 mth target $36.32.
    --------------------------------------------------------------------
    NOVOGEN LIMITED [NRT] $2.56 Hartleys - Hold. Positive preliminary results associated with company's anti-cancer drug candidate provide the key driver to recommendation. Forecast FY02 loss higher than own estimate.
    --------------------------------------------------------------------
    QBE INSURANCE GROUP LIMITED [QBE] $7.57 Merrill Lynch - Buy/LT Strong Buy. Target $8.00. Analysts believe company is arguably operating within the best pricing environment since mid-80's. Earnings momentum coming two years seen as likely attractive.
    --------------------------------------------------------------------
    RIO TINTO LIMITED [RIO] $36.31 Merrill Lynch - Buy/LT Strong Buy. Target 43.00. Cut FY02 profit to $1.764bn from $1.808bn, FY03 to $2.172bn from $2.186bn. On reported 7% lower thermal coal price settlement between Japan-Australia. Net Present value $33.00. See good value at current price. Prefer BHP Billiton [BHP] because of forecast higher upside.
    --------------------------------------------------------------------
    SOUTHERN CROSS BROAD [SBC] $9.60 Citigroup - Downgrade to Underperform, Low Risk from Neutral. As affiliation agreements with Ten [TEN] are about to expire in the second half of the current year, company is likely to forced to accept higher charges because of Ten's better ratings. Concerns about accounting and radio performances remain. Cut Discounted Cash Flow valuation by 7% to $8.70.
    --------------------------------------------------------------------
    ST GEORGE BANK LIMITED [SGB] $19.65 Goldman Sachs - Market Underperformer. Rapid growth seen slowing down. Takeover is not expected soon after June 1 and this is likely to see the stock underperform later this year.
    --------------------------------------------------------------------
    SINGAPORE TELECOMMUNICATIONS LIMITED. [SGT] $1.54 Hartleys - Sell. H1 result below market consensus.
    --------------------------------------------------------------------
    JB Were - Reduce/LT Sell. Cut FY03 EPS by 7%, FY04 by 23%. Primarily on lowered expectations for Singaporean data division, increased C2C losses and lower expectations for Optus Business division.
    --------------------------------------------------------------------
    JP Morgan - Market Underperformer. Result was in line with forecasts, but recommendation stays until Optus et al start to deliver better earnings.
    --------------------------------------------------------------------
    TELSTRA CORPORATION LIMITED. [TLS] $4.73 Citigroup - Neutral, Medium Risk. Expect company to further lose market share in data as Optus is committed to grow further in this market segment. In mobile, analysts believe company will be forced to increase subsidies and dealer commissions.
    --------------------------------------------------------------------
    TOWER LIMITED [TWR] $4.07 JB Were - Hold. Valuation $4.50. Revised H1 FY02 forecast to $34m from $43.6m as market returns on fixed assets have been lower than original anticipated.
    --------------------------------------------------------------------
    UNITED ENERGY LIMITED [UEL] $2.22 Deutsche Bank - Marketperform. Target $2.25. Possible disposal of Aquila's Australasian assets, including stake in company, adds to uncertainty surrounding outlook. View current ownership structure as insufficient and believe the matter should be addressed. Valuation $2.33.
    --------------------------------------------------------------------
    WATTYL LIMITED [WYL] $2.40 UBS Warburg - Hold. Cut FY02 earnings by $3.1m to $11m due to concerns over US turnaround and higher oil price. Lift target by 40c to $2.40 due to peer group's higher multiples.
    --------------------------------------------------------------------

    trader/investor/research resistance 0.891supp0.732.
    ---------------------------------------------------------------------
    http://www.stockhouse.com.au/bullboards/viewmessage.asp?no=5122129%20%20&tableid=1
    ---------------------------------------------------------------------
    3/5/02 12:11:58 PM
    ---------------------------------------------------------------------
    The price action is indicative (view) of a possible announcement occurring at sometime in the near future--for volumes have been rising and on trade data the lows are higher than the previous lows and the highs are higher than the previous highs.
    ---------------------------------------------------------------------
    http://www.equis.com/free/taaz/gannangles.html
    ---------------------------------------------------------------------
    High was 1.53 September 1st 2000 (Low 1.15 closed 1.51---vol 1.51 million)
    ---------------------------------------------------------------------
    1.53 x 82.5% equals 1.26.225--------1.53 minus 1.26.225 equals 27.225
    ---------------------------------------------------------------------
    27.225 x 82.5% equals 18.335625----27.225 minus 18.335625 equals 8.890625
    ---------------------------------------------------------------------
    Fridays Trade data dated 3/4/2002.
    ---------------------------------------------------------------------
    High 8.6 Low 8.4 Close 8.6 bollinger band 4/4/2002---lower 0.572 middle 0.732 upper 0.891
    ----------------------------------------------------------------------
    support is middle end of bollinger 0.732-----resistance is 0.891
    ----------------------------------------------------------------------
    http://www.equis.com/free/taaz/fibonacci.html
    ----------------------------------------------------------------------
    Low BNO---dated May 21st 2002 0.55 (close 0.57 high--0.59)
    ----------------------------------------------------------------------
    0.55 x 38.2% equals 0.2101 0.55 plus 0.2101 equals 5.7101---bollinger lower 3/4/2002 0.572 close May 1st 2002 0.57
    ----------------------------------------------------------------------

    BNO Bionomics Ltd FPO


    Total Trades Total Volume Last Trade V.W.A.P*
    6 34,808 78 77.9
    * Volume Weighted Average Price
    Trade
    Number (s) Time
    Last Traded Price Volume Change Value Number
    of Trades
    4 - 6 4:05:48 pm 78 30,308 1 $23,640 3
    1 - 3 12:58:16 pm 77 4,500 $3,465 3
    http://www.stockhouse.com.au/bullboards/viewmessage.asp?no=5183326&t=0&TableID=1



    ilrobbinrosso (ID#: 406483) RE: trade/invest/researchresistance0.891supp7.8 21/5/02 6:38:37 AM 5183326
    « Previous Message Next Message »

    One moment I think it is 7.8 and another moment I think it is 8.3---seriously though all jokes aside if you are looking at the company medium to longer term rather than a day trade---does half a cent really matter--LOL
    Cheers,--Steve.


    This message has been viewed 27 times
    Report a BullBoards Violation Ignore ilrobbinrosso Post View Threads

 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.002(2.56%)
Mkt cap ! $43.57M
Open High Low Value Volume
7.8¢ 8.1¢ 7.8¢ $25.20K 321.1K

Buyers (Bids)

No. Vol. Price($)
2 75923 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 297561 1
View Market Depth
Last trade - 15.47pm 17/01/2020 (20 minute delay) ?
(live)
Last
7.9¢
  Change
0.002 ( 0.00 %)
Open High Low Volume
8.0¢ 8.1¢ 7.8¢ 162114
Last updated 15.45pm 17/01/2020 (live) ?
BNO (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.